Results 111 to 120 of about 70,554 (222)

Orthotopic Esophageal Cancer Xenograft Model in Immunosuppressed Microminipigs for Near‐Infrared Fluorescence Endoscopy

open access: yesCancer Science, EarlyView.
We report the first successful orthotopic engraftment of human esophageal squamous cell carcinoma in immunosuppressed microminipigs and demonstrate high‐contrast near‐infrared fluorescence endoscopic detection using EGFR‐targeted cetuximab. This large‐animal model bridges preclinical imaging research and future clinical translation in esophageal cancer.
Takanori Miyake   +14 more
wiley   +1 more source

Complex Systems Analysis of Arrested Neural Cell Differentiation during Development and Analogous Cell Cycling Models in Carcinogenesis [PDF]

open access: yes, 2004
A new approach to the modular, complex systems analysis of nonlinear dynamics of arrested neural cell Differentiation--induced cell proliferation during organismic development and the analogous cell cycling network transformations involved in ...
Baianu, Professor I.C.   +1 more
core  

Triple negative breast cancer: new perspectives for targeted therapies [PDF]

open access: yes, 2015
Breast cancer is a heterogeneous disease, encompassing a large number of entities showing different morphological features and having clinical behaviors.
Caruso, Davide   +8 more
core   +1 more source

Inhibition of P‐glycoprotein using photoimmunotherapy in peritoneal metastasis mouse model

open access: yesPhotochemistry and Photobiology, EarlyView.
Photoimmunotherapy (PIT) using photoimmunoconjugates (PICs) can inhibit the function of the ATP‐binding cassette (ABC) transporter P‐glycoprotein (P‐gp) in a mouse model of peritoneal carcinomatosis. Sterile‐filtered PIC was administered in vivo via intraperitoneal (IP) injection 20 days after IP tumor cell implantation of P‐gp‐overexpressing NCI/ADR ...
Kaitlyn A. Moore   +6 more
wiley   +1 more source

Efficacy of Combined 5-Fluorouracil and Photodynamic Therapy in Glioma Spheroids

open access: yes, 2018
Standard treatment regimens consisting of surgery, radiation and chemotherapy have proven ineffective for the treatment of high-grade gliomas such as glioblastoma multiforme (GBM).
Singh, Karanjit
core   +1 more source

Transfusion‐related alpha‐gal syndrome: Two new cases expanding the demographic and geographic spectrum, and evidence of a diagnostic gap in allergic transfusion reaction evaluation

open access: yesTransfusion, EarlyView.
Abstract Background Transfusion‐related alpha‐gal syndrome (TRAGS) has recently been proposed as a cause of allergic transfusion reactions (ATRs) in which alpha‐gal‐specific IgE in sensitized group O (or potentially group A) recipients reacts with epitopes on group B or AB plasma‐containing components.
Mackenzie Foster   +9 more
wiley   +1 more source

Evaluation of the Physicochemical and Biological Stability of Cetuximab under Various Stress Condition

open access: yesJournal of Pharmacy & Pharmaceutical Sciences, 2019
Cetuximab is a chimeric monoclonal antibody against epidermal growth factor receptor (EGFR) and it is approved for treatment of human colorectal cancer and squamous cell carcinoma of head and neck.
Afsaneh Farjami   +4 more
doaj   +1 more source

Light‐Triggered Antibody‐Photosensitizer Conjugates Disrupt P‐Glycoprotein Function to Reverse Multidrug Resistance

open access: yesAdvanced Therapeutics, Volume 9, Issue 4, April 2026.
Advanced ovarian cancer has a poor prognosis largely due to chemoresistance driven by ATP‐binding cassette (ABC) drug efflux transporters, especially P‐glycoprotein (P‐gp, or ABCB1). While photodynamic therapy (PDT) with FDA‐approved benzoporphyrin derivative (BPD) can inhibit ABC transporters, BPD alone lacks cancer selectivity.
Kathryn L. McNaughton   +6 more
wiley   +1 more source

Berberine: a promising strategy to combat cetuximab-resistance in colorectal cancer

open access: yesBMC Cancer
Cetuximab, a monoclonal antibody against epidermal growth factor receptor (EGFR), is approved as a front-line treatment for metastatic colorectal cancers, but limited efficacy is obtained.
Jianmin Ye   +6 more
doaj   +1 more source

Combining Small‐Molecular Compounds With CAR T‐Cell Therapy: Novel Strategies for Enhanced Cancer Immunotherapy

open access: yesCancer Innovation, Volume 5, Issue 2, April 2026.
Chimeric antigen receptor (CAR) T‐cell therapy, although revolutionary for haematological malignancies, faces significant challenges, including T‐cell exhaustion, limited persistence, and treatment‐related toxicity. The integration of small‐molecule compounds offers a promising strategy to overcome these limitations.
Rangzi Yi   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy